New Combination Therapy for Advanced Small Cell, Lung Cancer Approved in Australia and Singapore

ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), is approved for use in Australia and Singapore as a first-line maintenance treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) [1],[2] SCLC is an aggressive form of lung cancer,...